Neuphoria Therapeutics Inc.: Form 20-F for the period ended Jun 30, 2023
Filed with the SEC on Oct 18, 2023 and accepted by EDGAR at Oct 18, 2023, 10:42 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-07-01 to 2023-06-30 | AUD 22.0k | ifrs-full:Revenue |
| Shares outstanding | At period end2023-06-30 | 1,486,735,424 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000950170-23-053873. Last ingested by Listed: Oct 24, 2026, 15:10 ET. Listed shows no prices and gives no investment advice.